|Bid||47.50 x 100|
|Ask||64.00 x 200|
|Day's Range||59.62 - 61.16|
|52 Week Range||35.00 - 64.51|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.95%|
Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...
Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...
The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...
Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn't meet its primary endpoint. Horizon stock fell 22.5% that day.
Markets have had a week to digest the shift in direction due to the election. Waiting for pullbacks and flattening patterns is still a working strategy.
** iShares Nasdaq Biotechnology ETF hitting fresh 3-mth lows; bear trend from its late Sept high remains intact ** IBB falling 2.5 pct, bringing YTD loss to 23.5 pct; stark contrast to 25 pct 2016 rise ...